Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOs
→ For the first time since he sold Celgene to Bristol Myers Squibb for $74 billion in 2019, Mark Alles is a CEO again. Alles had been chairing the board at TORL Biotherapeutics, an antibody maker from UCLA’s Dennis Slamon, and will now pace the sidelines as CEO of the company. Since the Celgene buyout, Alles has shown up occasionally in Peer Review by taking board appointments, including the role of chairman at AI Proteins, Wugen and Turning Point Therapeutics, which also caught the eye of Bristol Myers. Looking to cash in on the antibody-drug conjugate craze, TORL launched last April and nabbed $158 million in Series B financing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.